Boston Scientific (NYSE:BSX) commences concurrent $750M offerings of common stock and Series A mandatory convertible preferred stock.

Prices, volumes and terms have yet to be announced.

A portion of the net proceeds will fund the repayment of current borrowings.

READ FULL ARTICLE HERE